文献速递艾滋病与性传播感染

泰国HIV感染跨性别女性中FHT与ART的药物相互作用:iFACT研究

Drug-drug Interactions Among Thai Transgender Women Living with Human Immunodeficiency Undergoing Feminizing Hormone Therapy and Antiretroviral Therapy: The iFACT Study.
PubMed 文献 · Clin Infect Dis · 2021-01-01

iFACT研究纳入20例新诊断HIV感染的泰国跨性别女性,采用密集PK采样评估雌二醇(E2)与替诺福韦/恩曲他滨/依非韦伦(EFV)方案间的药物相互作用。结果显示,合用ART时E2的AUC、Cmax和C24显著降低;合用FHT时TFV的AUC、C24及EFV的C24也显著降低。

要点

  • EFV方案使E2的AUC、Cmax和C24分别降至0.72、0.81和0.64倍。
  • FHT使TFV的AUC、C24及EFV的C24分别降至0.86、0.83和0.91倍。
  • 需进一步研究上述PK降低是否具有临床意义。

核心结论

  • 在HIV阳性跨性别女性中,含EFV的ART显著降低E2的PK参数,而FHT也降低部分TFV和EFV的PK参数。

研究设计与样本

  • 前瞻性药代动力学研究,纳入20例新诊断HIV感染的泰国跨性别女性。
  • FHT(戊酸雌二醇2 mg/d+醋酸环丙孕酮25 mg/d)从基线用至第5周,第8周重启;ART(TDF/FTC/EFV 300/200/600 mg)第3周启动。
  • 在第3周(无ART)和第5周(有ART)密集测定E2 PK;在第5周(有FHT)和第8周(无FHT)密集测定TFV和EFV PK。

临床怎么用

  • 对同时使用FHT和含EFV ART的跨性别女性,应关注E2暴露降低及TFV/EFV暴露轻度降低的可能。
  • 需结合临床监测评估激素疗效和抗病毒疗效,必要时考虑调整方案。

局限性

  • 样本量小(20例),仅评估一种FHT方案和一种ART方案。
  • 未确定PK降低的临床意义,结果不能外推至其他FHT或ART方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Drug-drug interactions between feminizing hormone therapy (FHT) and antiretroviral therapy (ART) are a major concern among transgender women (TGW), which may lead to suboptimal ART adherence and inappropriate FHT dosage. To evaluate potential drug-drug interactions between FHT and ART, we performed intensive measurements of the pharmacokinetic (PK) parameters of blood tenofovir (TFV), efavirenz (EFV), and estradiol (E2). METHODS: Twenty TGW with newly diagnosed human immunodeficiency virus (HIV) infection were enrolled. FHT (E2 valerate 2 mg/d and cyproterone acetate 25 mg/d) was prescribed at baseline until week 5 and restarted at week 8. ART (TFV disoproxil fumarate/emtricitabine/EFV at 300/200/600 mg) was initiated at week 3. The E2 PK parameters were measured intensively at weeks 3 (without ART) and 5 (with ART), and TFV and EFV PK parameters were measured intensively at weeks 5 (with FHT) and 8 (without FHT). RESULTS: The median (interquartile range) age and body mass index were 25.5 (22.5-31.0) years and 20.6 (19.3-23.1) kg/m2, respectively. The differences in geometric mean ratios between weeks 3 and 5 were as follows for E2 area under the curve, maximum concentration, and concentration at 24 hours (C24), respectively: 0.72 (90% confidence interval, .64-.81; P < .001), 0.81 (.72-.92; P = .006), and 0.64 (.50-.83; P = .004). The differences in geometric mean ratios between weeks 5 and 8 were as follows for TFV AUC, TFV C24, and EFV C24: 0.86 (90% confidence interval, .80-.93; P = .002), 0.83 (.75-.93; P = .006), and 0.91 (.85-.97; P = .02). CONCLUSIONS: Among HIV-positive TGW, E2 PK parameters were significantly lower in the presence of TFV disoproxil fumarate/emtricitabine/EFV, and some TFV and EFV PK parameters were lower in the presence of FHT. Further studies should determine whether these reductions are clinically significant and whether they occur with other FHT or ART regimens.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Hiransuthikul A, Himmad L, Kerr SJ, et al. Drug-drug Interactions Among Thai Transgender Women Living with Human Immunodeficiency Undergoing Feminizing Hormone Therapy and Antiretroviral Therapy: The iFACT Study. Clin Infect Dis. 2021. PMID: 31942947. doi:10.1093/cid/ciaa038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。